Formulation: A solid
Formal Name: 1,1'-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)azanediyl)bis(dodecan-2-ol)
Purity: ≥98%
Formula Markup: C46H73N5O2
Formula Weight: 728,1
Shelf life (days): 1460
Notes: C12-TLRa is an adjuvant lipidoid (pKa = 6.42) with toll-like receptor 7/8 (TLR7/8) agonist activity.{69436} Lipid nanoparticles (LNPs) containing C12-TLRa as a partial replacement for the ionizable lipidoid C12-113 (Item No. 39335) and encapsulating luciferase mRNA exhibit TLR7 agonist activity in HEK reporter cells and induce TNF-α production in DC2.4 cells. LNPs containing C12-TLRa and encapsulating luciferase mRNA have improved mRNA transfection and duration and induce a larger increase in the percentage of mature dendritic cells in mice when compared to LNPs containing C12-113. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-LNP vaccine containing C12-TLRa induces higher serum IgG titers to the SARS-CoV-2 receptor-binding domain (RBD), as well as a higher number of CD80+PD-L2+ RBD-specific B cells, in the spleen in mice.
English
Deutsch
